Ubrogepant Can Be Safely Used with Apixaban and Sertraline
Yes, ubrogepant is safe to use concurrently with apixaban and sertraline (Zoloft), as there are no clinically significant drug interactions between these medications.
Drug Interaction Analysis
Ubrogepant and Apixaban
Ubrogepant does not interact with apixaban through any clinically relevant mechanism. The FDA label for ubrogepant 1 specifies that dose adjustments are only required for:
- Strong CYP3A4 inhibitors (contraindicated)
- Moderate or weak CYP3A4 inhibitors or inducers
- BCRP and/or P-gp inhibitors
Apixaban is not a CYP3A4 inhibitor, inducer, or significant P-gp/BCRP inhibitor. While apixaban is metabolized by CYP3A4 and is a P-gp substrate 2, it does not inhibit these pathways in a way that would affect ubrogepant metabolism. The FDA label explicitly states that ubrogepant showed no significant pharmacokinetic interactions with multiple co-administered drugs tested 1, and the interaction profile is well-characterized.
Ubrogepant and Sertraline
Sertraline (Zoloft) is a selective serotonin reuptake inhibitor (SSRI) that has minimal CYP3A4 inhibitory effects. Sertraline is not listed as a strong, moderate, or even weak CYP3A4 inhibitor requiring dose adjustment for ubrogepant. The FDA label for ubrogepant does not identify SSRIs as interacting medications 1.
Apixaban and Sertraline
There is no clinically significant interaction between apixaban and sertraline. Apixaban's metabolism involves CYP3A4 and P-gp 2, but sertraline does not meaningfully inhibit these pathways at therapeutic doses.
Clinical Recommendations
Use standard dosing for all three medications:
- Ubrogepant: 50 mg or 100 mg as needed for acute migraine (maximum 200 mg per 24 hours) 3, 1
- Apixaban: Continue prescribed dose (typically 5 mg twice daily for most indications)
- Sertraline: Continue prescribed dose
Important Caveats
Monitor for bleeding risk - While the drug interaction is not the concern, apixaban itself carries bleeding risk. The combination of multiple medications should prompt routine assessment of bleeding signs (bruising, bleeding gums, blood in urine/stool).
Avoid strong CYP3A4 inhibitors with ubrogepant - Medications like ketoconazole, itraconazole, clarithromycin, and ritonavir are contraindicated with ubrogepant 1. These would increase ubrogepant exposure 5-10 fold 1.
Avoid strong CYP3A4 inducers with ubrogepant - Rifampin and similar inducers reduce ubrogepant exposure by 80% 1, rendering it ineffective.
Recent safety data supports gepant use - A 2024 study demonstrated that concomitant use of ubrogepant with another gepant (atogepant) was safe and well-tolerated over 12 weeks 4, suggesting gepants have a favorable safety profile even with complex medication regimens.